docetaxelabirateronedarolutamideARASENSenzalutamideapalutamidePEACE-1mHSPCde novo mHSPCmetastatic hormone-sensitive prostate cancer (mHSPC)+4 more
…eceived abiraterone, 31% apalutamide, 26% enzalutamide, and 11% docetaxel. Median PFS and OS were 32 and 50 months, respectively, in the …